Satellos Bioscience Inc.

Satellos Bioscience Inc. is a clinical-stage biotechnology and drug development company headquartered in Toronto, Ontario, Canada. The company's core business is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Its mission is to improve the treatment of Duchenne muscular dystrophy (DMD) and other devastating muscle diseases by regenerating muscle through novel small molecule therapeutics.

Satellos' lead product is SAT-3247, a first-of-its-kind, orally administered small molecule drug. This therapeutic targets AAK1, a key protein identified by Satellos as capable of helping restore muscle stem-cell signaling, a process disrupted in DMD. The company is initially focused on developing SAT-3247 as a potential disease-modifying treatment for DMD. Additionally, Satellos leverages its proprietary MyoReGenX™ discovery platform to identify other degenerative muscle conditions where deficits in muscle stem cell polarity and regeneration can be therapeutically addressed.

Led by Co-founder and CEO Frank Gleeson, Satellos Bioscience Inc. has recently achieved significant milestones. In February 2026, the company completed a US$57.2 million equity financing and commenced trading on the Nasdaq Global Market under the ticker "MSLE". Satellos has initiated two Phase 2 clinical trials for SAT-3247 in DMD patients: BASECAMP (pediatric) and TRAILHEAD (adult). Interim data from the TRAILHEAD study, presented in March 2026, indicated continued improvement in handgrip strength and reductions in established DMD biomarkers. Preclinical data also suggest the potential expansion of SAT-3247 into facioscapulohumeral muscular dystrophy (FSHD). Leerink initiated coverage of Satellos with an Outperform rating in April 2026, recognizing its differentiated approach to muscle regeneration.